198 related articles for article (PubMed ID: 24261996)
1. Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism.
Schnoeller C; Roux X; Sawant D; Raze D; Olszewska W; Locht C; Openshaw PJ
Am J Respir Crit Care Med; 2014 Jan; 189(2):194-202. PubMed ID: 24261996
[TBL] [Abstract][Full Text] [Related]
2. Non-specific Effects of Live Attenuated Pertussis Vaccine Against Heterologous Infectious and Inflammatory Diseases.
Cauchi S; Locht C
Front Immunol; 2018; 9():2872. PubMed ID: 30581436
[No Abstract] [Full Text] [Related]
3. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.
Thorstensson R; Trollfors B; Al-Tawil N; Jahnmatz M; Bergström J; Ljungman M; Törner A; Wehlin L; Van Broekhoven A; Bosman F; Debrie AS; Mielcarek N; Locht C
PLoS One; 2014; 9(1):e83449. PubMed ID: 24421886
[TBL] [Abstract][Full Text] [Related]
4. IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine.
Solans L; Debrie AS; Borkner L; Aguiló N; Thiriard A; Coutte L; Uranga S; Trottein F; Martín C; Mills KHG; Locht C
Mucosal Immunol; 2018 Nov; 11(6):1753-1762. PubMed ID: 30115992
[TBL] [Abstract][Full Text] [Related]
5. Live attenuated B. pertussis BPZE1 rescues the immune functions of Respiratory Syncytial virus infected human dendritic cells by promoting Th1/Th17 responses.
Schiavoni I; Fedele G; Quattrini A; Bianco M; Schnoeller C; Openshaw PJ; Locht C; Ausiello CM
PLoS One; 2014; 9(6):e100166. PubMed ID: 24967823
[TBL] [Abstract][Full Text] [Related]
6. Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice.
Kammoun H; Feunou PF; Foligne B; Debrie AS; Raze D; Mielcarek N; Locht C
Vaccine; 2012 Aug; 30(40):5864-70. PubMed ID: 22814407
[TBL] [Abstract][Full Text] [Related]
7. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model.
Kavanagh H; Noone C; Cahill E; English K; Locht C; Mahon BP
Clin Exp Allergy; 2010 Jun; 40(6):933-41. PubMed ID: 20184606
[TBL] [Abstract][Full Text] [Related]
8. Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models.
Li R; Cheng C; Chong SZ; Lim AR; Goh YF; Locht C; Kemeny DM; Angeli V; Wong WS; Alonso S
Allergy; 2012 Oct; 67(10):1250-8. PubMed ID: 22909095
[TBL] [Abstract][Full Text] [Related]
9. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.
Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C
Vaccine; 2010 Oct; 28(43):7047-53. PubMed ID: 20708998
[TBL] [Abstract][Full Text] [Related]
10. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.
Skerry CM; Mahon BP
Clin Vaccine Immunol; 2011 Feb; 18(2):187-93. PubMed ID: 21147936
[TBL] [Abstract][Full Text] [Related]
11. Live attenuated Bordetella pertussis vaccine candidate BPZE1 transiently protects against lethal pneumococcal disease in mice.
Belcher T; Kammoun H; Coutte L; Debrie AS; Mielcarek N; Sirard JC; Cauchi S; Locht C
Vaccine; 2022 Mar; 40(11):1555-1562. PubMed ID: 33509692
[TBL] [Abstract][Full Text] [Related]
12. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis.
Feunou PF; Bertout J; Locht C
PLoS One; 2010 Apr; 5(4):e10178. PubMed ID: 20419113
[TBL] [Abstract][Full Text] [Related]
13. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.
Mielcarek N; Debrie AS; Mahieux S; Locht C
Clin Vaccine Immunol; 2010 Mar; 17(3):317-24. PubMed ID: 20107007
[TBL] [Abstract][Full Text] [Related]
14. Early Protection against Pertussis Induced by Live Attenuated
Debrie AS; Mielcarek N; Lecher S; Roux X; Sirard JC; Locht C
J Immunol; 2019 Dec; 203(12):3293-3300. PubMed ID: 31732529
[TBL] [Abstract][Full Text] [Related]
15. Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice.
Feunou PF; Kammoun H; Debrie AS; Locht C
Vaccine; 2014 Jul; 32(34):4281-8. PubMed ID: 24950361
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.
Jahnmatz M; Richert L; Al-Tawil N; Storsaeter J; Colin C; Bauduin C; Thalen M; Solovay K; Rubin K; Mielcarek N; Thorstensson R; Locht C;
Lancet Infect Dis; 2020 Nov; 20(11):1290-1301. PubMed ID: 32687804
[TBL] [Abstract][Full Text] [Related]
17. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.
Skerry CM; Cassidy JP; English K; Feunou-Feunou P; Locht C; Mahon BP
Clin Vaccine Immunol; 2009 Sep; 16(9):1344-51. PubMed ID: 19625486
[TBL] [Abstract][Full Text] [Related]
18. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
[TBL] [Abstract][Full Text] [Related]
19. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
Li R; Lim A; Alonso S
Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
[TBL] [Abstract][Full Text] [Related]
20. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.
Jahnmatz M; Amu S; Ljungman M; Wehlin L; Chiodi F; Mielcarek N; Locht C; Thorstensson R
Vaccine; 2014 Jun; 32(27):3350-6. PubMed ID: 24793938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
